Search Results
Found 3 results
510(k) Data Aggregation
(112 days)
Indications for Use statement for the MX100 and X3:
The monitor is indicated for use by healthcare professionals whenever there is a need for monitoring the physiological parameters of patients.
The monitor is intended to be used for monitoring and recording of, and to generate alarms for, multiple physiological parameters of adults, pediatrics, and neonates. The monitor is intended for use by trained healthcare professionals in a hospital environment.
The monitor is also intended for use during patient transport inside the hospital environment.
The monitor is only for use on one patient at a time. It is not intended for home use. Not a therapeutic device. The monitor is for prescription use only.
The ECG measurement is intended to be used for diagnostic recording of rhythm and detailed morphology of complex cardiac complexes (according to AAMI EC 11).
ST segment monitoring is intended for use with adult patients only and is not clinically validated for use with neonatal and pediatric patients.
The Integrated Pulmonary Index (IPI) is intended for use with adult and pediatric (1 to 12 years) patients only. The IPI is an adjunct to and not intended to replace vital sign monitoring.
The Masimo rainbow SET measurement is indicated for the noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate, carboxyhemoglobin saturation (SpCO), methemoglobin saturation (SpMet), total hemoglobin concentration (SpHb), and/or respiratory rate (RRac). The Masimo rainbow SET measurement is indicated for use during both no motion and motion conditions, and for patients who are well or poorly perfused.
Indications for Use statement for the Hemodynamic Extension 867039:
The measurement extension adds physiological measurements to a dedicated host device. It is intended for use by trained healthcare professionals for adult, pediatric, and neonatal patients in a hospital environment and for transport inside hospitals. The measurement extension can only function when it is connected to a dedicated host device.
The new IntelliVue Patient Monitor MX100, Multi-Measurement Module X3, and Hemodynamic Extension 867039 acquire multiple physiological patient signals, display measurement values, waves and trends, generate physiological and technical alarms, provide data recording and support patient data management. The devices offer a monitoring solution optimized for the surgical, cardiac, medical and neonatal care environments. They can be located in the patient vicinity at the bedside or can be used mobile, during patient transport inside hospitals. The measurement sensors are applied at diverse bodily locations, depending on the actual physiological parameters monitored.
The new devices have the same range of functions as the legally marketed predicate devices. They use the same measurement parameters as the predicates.
Whereas the predicate devices optionally provide one invasive pressure, the new devices optionally provide two invasive pressures (dual pressure) that can be measured with one pressure connector.
The MX100 and X3 provide multiple non-invasive and invasive measurements: ECG (including arrhythmia and ST), respiration, SpO2, NBP, dual invasive pressure, temperature, and CO2.
The Hemodynamic Extension 867039 adds optional measurements: dual invasive pressure, temperature, and cardiac output /continuous cardiac output to the host device. The measurement extension can only function when it is connected to a dedicated host device.
Specifications of all measurement characteristics, including measurement principles, methods, algorithms, and all detailed performance specifications and measurement alarm specifications, are the same as those in the predicate devices. The new devices reuse unchanged existing accessories of the predicates.
The new IntelliVue Patient Monitor MX100 and Multi-Measurement Module X3 are compact, rugged, lightweight monitors with built-in measurements. The X3 can be used in two ways: as a multi-measurement module for the Philips IntelliVue family of patient monitors and as a stand-alone monitor.
The MX100 and X3 have a 6.1' TFT flat panel color display with a multi-finger touchscreen as input device.
The MX100 and X3 can interact with the Central Station via LAN or wireless link.
The new Transpac IV Dual IBP Cable 453564588501 is a reusable cable intended to connect two ICU Transpac pressure transducers with one of the new Philips measuring devices (Patient Monitor MX100, Multi-Measurement Module X3, or Hemodynamic Extension 867039). The cable transmits analog voltage signals from the pressure transducers to the Philips device and provides electrical power from the Philips device to the transducers.
Here's a breakdown of the acceptance criteria and study information for the Philips IntelliVue Patient Monitor MX100, Multi-Measurement Module X3, and IntelliVue Hemodynamic Extension 867039, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
The document does not provide a specific table of acceptance criteria with corresponding performance metrics in a concise format. Instead, it refers to fulfilling requirements of various recognized consensus standards and device-specific guidance documents. The general statement is:
Acceptance Criteria Category | Reported Device Performance |
---|---|
Safety and Essential Performance | All applicable requirements of AAMI / ANSI ES60601-1:2005/(R)2012 and A1:2012 (Ed. 3.1) met. |
Electromagnetic Compatibility (EMC) | All applicable requirements of IEC 60601-1-2: 2007 (Ed. 3) met. |
Electrocardiographs | All applicable requirements of IEC 60601-2-25: 2011 (Ed. 2) met. |
ECG Monitoring Equipment | All applicable requirements of IEC 60601-2-27: 2011 (Ed. 3) met. |
Automated Noninvasive Sphygmomanometers (NBP) | All applicable requirements of IEC 80601-2-30: 2013 (Ed. 1.1) met. Also, intra-device variability and comparison to intra-arterial reference standard for mean blood pressure met requirements of "Non-Invasive Blood Pressure (NIBP) Monitor Guidance." |
Invasive Blood Pressure Monitoring Equipment | All applicable requirements of IEC 60601-2-34: 2011 (Ed. 3) met. |
Respiratory Gas Monitors (CO2) | All applicable requirements of ISO 80601-2-55: 2011 (Ed. 1) met. |
Clinical Thermometers | All applicable requirements of ISO 80601-2-56: 2009 (Ed. 1) met. |
Pulse Oximeters (SpO2) | All applicable requirements of ISO 80601-2-61: 2011 (Ed. 1) met. Also, accuracy of Pulse Oximeters testing (demonstrating SpO2 and pulse rate values not corrupted during communication and display values, outputs, and indicators) met requirements of "Pulse Oximeters Premarket Notification Submissions [510(k)s] Guidance for Industry and Food and Drug Administration Staff." |
Software Life Cycle Processes | All applicable requirements of AAMI ANSI IEC 62304:2006 (Ed. 1) met. |
Usability | All applicable requirements of IEC 60601-1-6: 2013 (Ed. 3.1) met. Also, Usability and User Preference Testing confirmed safety and effectiveness. |
Alarms | All applicable requirements of IEC 60601-1-8: 2012 (Ed. 2.1) met. Also, Alarm, Measurement, Operating System, Display and Operation Unit Tests met requirements. |
Hazard Analysis | All specified pass/fail criteria met, confirming effectiveness of risk mitigation. |
Environmental and Mechanical Testing | All specified test requirements (temperature, humidity, mechanical classes 7M1, 7M2, 7M3, and disinfectant resistance) met. |
Unit, Integration, Functional, and Regression Testing | All specified test requirements met, demonstrating correct function of modified and previously available features. |
Respiration Rate and Cardiac Output Performance | All specified test requirements met, matching predicate device criteria for accuracy, resolution, bandwidth, alarm delay, repeatability, thermodilution curve visibility, drift limits, and small signal warnings. |
Transpac IV Dual IBP Cable Durability | All durability tests passed for cleaning, disinfection, mechanical/tensile strength, connector insertion/removal force, operating temperature, and connector insertion cycle. |
2. Sample Size Used for the Test Set and Data Provenance
The document does not explicitly state the sample sizes used for various test sets in terms of patient numbers or data records.
- NIBP testing: "minimum of three devices" were compared for intra-device variability.
- Data Provenance: Not specified. The document describes a series of engineering tests and compliance to standards, rather than clinical trials with patient data.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications
This information is not provided in the document. The studies described are primarily engineering verification and validation against established standards and predicate device specifications, rather than relying on expert ground truth for patient data in the typical sense of a diagnostic AI product.
4. Adjudication Method for the Test Set
This information is not applicable and not provided. The testing described is against defined technical specifications and standards, not a diagnostic task requiring adjudication of expert interpretations.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
A Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not explicitly mentioned or performed. This device is a patient monitor, not an AI-assisted diagnostic tool that aids human readers in interpreting medical images or data. The focus is on the device's accuracy and reliability in measuring and displaying physiological parameters.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done
The device is inherently a "standalone" system in terms of its algorithmic performance for measuring physiological parameters. The studies described (e.g., NIBP accuracy, SpO2 accuracy, respiration rate accuracy) directly assess the device's algorithms and hardware without requiring human intervention in the measurement process itself, though it is intended for use by healthcare professionals.
7. The Type of Ground Truth Used (expert consensus, pathology, outcomes data, etc.)
The ground truth for the performance testing appears to be based on:
- Reference Standards: For parameters like NIBP, a "comparison to the intra-arterial reference standard for mean blood pressure" was used.
- Predicate Device Specifications: The "Pass/Fail criteria were based on the specifications cleared for the predicate devices."
- Consensus Standards: Performance was evaluated against recognized consensus standards (e.g., IEC, AAMI, ISO) which define acceptable limits for accuracy and performance.
8. The Sample Size for the Training Set
This information is not applicable and not provided. The document describes a medical device, not a machine learning or AI model that requires a "training set" in the conventional sense. The device's algorithms are likely based on established physiological principles and engineering design, not data-driven machine learning models that are "trained."
9. How the Ground Truth for the Training Set Was Established
This information is not applicable and not provided, as there is no mention of a "training set" for a machine learning algorithm.
Ask a specific question about this device
(163 days)
The monitor is indicated for use by healthcare professionals whenever there is a need for monitoring the physiological parameters of patients. The monitor is intended to be used for monitoring and recording of, and to generate alarms, for, multiple physiological parameters of adults, pediatrics, and neonates. The monitor is intended for use by trained healthcare professionals in a hospital environment. The monitor is also intended for use during patient transport inside and outside of the hospital environment. The monitor is only for use on one patient at a time. It is not intended for home use. Not a therapeutic device. The monitor is for prescription use only. The ECG measurement is intended to be used for diagnostic recording of rhythm and detailed morphology of complex cardiac complexes (according to AAMI EC 11). ST segment monitoring is intended for use with adult patients only and is not clinically validated for use with neonatal and pediatric patients. The Predictive Temperature unit is intended for use with adult and pediatric patients in a hospital environment. The SSC Sepsis Protocol, in the ProtocolWatch clinical decision support tool, is intended for use with adult patients only. The derived measurement Pulse Pressure Variation (PPV) is intended for use with sedated patients receiving controlled mechanical ventilation and mainly free from cardiac arrhythmia. The PPV measurement has been validated only for adult patients. The transcutaneous gas measurement (tcGas) is restricted to neonatal patients only. BIS is intended for use under the direct supervision of a licensed health care practitioner or by personnel trained in its proper use. It is intended for use on adult and pediatric patients within a hospital or medical facility providing patient care to monitor the state of the brain by data acquisition of EEG signals. The BIS may be used as an aid in monitoring the effects of certain anesthetic agents. Use of BIS monitoring to help guide anesthetic administration may be associated with the reduction of the incidence of awareness with recall in adults during general anesthesia and sedation.
The Philips IntelliVue Patient Monitors family comprises the multiparameter patient monitor series: MP2, X2, MP5, MP5T, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MP90 and MX600, MX700, and MX800. Each monitor consists of a display unit including built-in or separate central processing unit (CPU) and physiological measurement modules. All monitors share the same architecture of CPU units and exactly the same software is executed on each monitor. The monitors measure physiological parameters such as: Sp02, pulse, ECG, arrhythmia, ST, QT, respiration, invasive and noninvasive blood pressure, temperature, CO2, spirometry, C.O., CCO, tcp02/ tcpCO2, S02, Sv02, Scv02, EEG, and BIS. They generate alarms, record physiological signals, store derived data, and communicate derived data and alarms to the central station. IntelliVue series MP2, X2, MP5, MP5T, MP5SC, MP20, and MP30 are robust, portable, lightweight, compact in size and modular in design patient monitors with interfaces to dedicated external measurement devices. Models MP2, X2, MP5, MP5T, and MP5SC also incorporate multiple built-in physiological measurements. IntelliVue series MP40, MP50, MP60, MP70, MX600, MX700, and MX800 are patient monitors with built-in central processing unit, flat panel display and interfaces to dedicated external measurement devices. Models MX600, MX700, and MX800 have widescreen displays. IntelliVue series MP80 and MP90 are patient monitors with flat panel display and central processing unit as separate components. They have interfaces to dedicated external measurement devices.
Here's a breakdown of the acceptance criteria and the study information based on the provided text, structured as requested:
Acceptance Criteria and Device Performance Study for Philips IntelliVue Patient Monitors (Software Revision J.04)
Overview:
The submission describes a software modification to existing Philips IntelliVue Patient Monitors (MP2, X2, MP5, MP5T, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MP90, MX600, MX700, and MX800) to introduce a new SpO2 intelligent alarm delay feature called 'Smart Alarm Delay'. The study aims to demonstrate that this modified device is as safe and effective as the predicate devices.
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly present a quantitative table of acceptance criteria with corresponding performance metrics for the 'Smart Alarm Delay' feature in the format often seen for diagnostic devices (e.g., sensitivity, specificity, accuracy). However, the "Summary of V&V activities" section outlines the general performance goals and outcomes.
Acceptance Criteria Category | Specific Criteria/Goal | Reported Device Performance |
---|---|---|
Clinical Evaluation | Users' understanding of the 'Smart Alarm Delay' feature as described in the Instructions for Use (IFU). | "The vast majority of test persons understood the implications of using the new SpO2 Smart Alarm Delay feature." |
Users' perception of the feature's usefulness and clinical meaningfulness. | "They regarded it as a helpful alternative to the existing SpO2 standard alarm delay." | |
Functionality Testing | Effectiveness of implemented design risk mitigation measures (from Hazard Analysis). | "The test results have confirmed the effectiveness of implemented design risk mitigation measures." |
Safe, effective, and according to specifications and IFU for SpO2 alarm derivation and delays of modified software. | "All specified criteria have been met. The test results have confirmed that the SpO2 alarm derivation and the SpO2 alarm delays of the modified IntelliVue Monitors have functioned safe, effective and according to the specifications and Instructions for Use." | |
Regression Testing | Functionality of related, unmodified software parts. | "All specified criteria have been met. The test results have confirmed that the SpO2 parameter of the modified IntelliVue Monitors have functioned safe, effective and according to the specifications and Instructions for Use." |
Functionality of alarms of the IntelliVue Patient Monitors. | "All specified criteria have been met. The test results have confirmed that the alarms of the modified IntelliVue Monitors have functioned safe, effective and according to the specifications and Instructions for Use." | |
Performance (Accuracy/Safety) | Device performance, accuracy, and compliance with SpO2 standard ISO 9919. | "The modification does not affect device performance in general and device accuracy in particular... The modification does also not affect any safety and performance aspects covered by the SpO2 standard ISO 9919. Therefore, verification and validation executed on the subject IntelliVue Patient Monitors according to the standard ISO 9919 prior to the minor modification... is still valid and covers the modified devices." |
2. Sample Size and Data Provenance for the Test Set
- Sample Size: The document does not specify the exact number of individuals (test persons) involved in the clinical evaluation. It refers to "two user groups - one consisting of physicians and one consisting of nurses" and later "the vast majority of test persons." This suggests a qualitative assessment rather than a statistically powered performance study.
- Data Provenance: Not explicitly stated, but clinical evaluation of user understanding implies prospective testing with healthcare professionals. The country of origin for this specific clinical evaluation is not mentioned.
3. Number of Experts and Qualifications for Ground Truth of the Test Set
- The "clinical evaluation" appears to focus on user comprehension and acceptance, not on establishing a traditional clinical "ground truth" for diagnostic accuracy.
- Number of Experts: Two user groups were formed: "one consisting of physicians and one consisting of nurses." The exact number of individuals within each group is not provided.
- Qualifications of Experts:
- Physicians
- Nurses
- No specific years of experience or subspecialty are mentioned.
4. Adjudication Method for the Test Set
Not applicable. The clinical evaluation described is a qualitative assessment of user understanding and perception, not a diagnostic accuracy study requiring adjudication of results.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No. The document describes a software modification to an existing patient monitor to add an intelligent alarm delay feature. The "clinical evaluation" focused on user understanding and acceptance of this feature, not on comparing reader performance with and without AI assistance.
6. Standalone Performance Study (Algorithm Only)
No, not in the traditional sense of a standalone diagnostic algorithm performance study. The modification is an alarm delay feature within an existing monitoring system. The document states:
- "The new 'Smart Alarm Delay' feature is isolated from the SpO2 measurement algorithm, i.e. signal acquisition and numeric processing."
- "The devices hardware and all accessories including, but not limited to the SpO2 sensors remain completely unchanged."
- "The modification does not affect device performance in general and device accuracy in particular."
- Performance aspects covered by ISO 9919 from prior V&V are considered still valid.
This indicates that the fundamental SpO2 measurement accuracy itself was not re-evaluated as a standalone algorithm performance, as the algorithm for SpO2 measurement remained unchanged. The focus was on the alarm delay logic and its user-facing implications.
7. Type of Ground Truth Used
For the "clinical evaluation" regarding the 'Smart Alarm Delay' feature, the "ground truth" appears to be user understanding and subjective opinion as gathered directly from physicians and nurses. For the core SpO2 measurement, the ground truth and performance validation are based on prior verification and validation activities conducted according to ISO 9919 for the predicate device, which are deemed still valid.
8. Sample Size for the Training Set
Not applicable. This submission is for a software modification adding an alarm delay feature, not a machine learning or AI algorithm that requires a dedicated training set for model development. The 'Smart Alarm Delay' is described as being "based on the same fundamental principle" as the predicate's 'SatSeconds' alarm management technique, implying a rule-based or empirically derived logic rather than a learned model.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as no training set for a machine learning model was described or used.
Ask a specific question about this device
(21 days)
Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. Intended for monitoring and recording of and to generate alarms for multiple physiological parameters of adults, pediatrics and neonates in hospital environments. The MP2, X2, MP20, MP30, MP40, and MP50 are additionally intended for use in transport situations within hospital environments. The MP5 is also intended for use during patient transport outside of a hospital environment.
The Philips MP2, X2, MP5, MP20, MP30, MP40, MP50, MP60, MP70, MP80, and MP90 IntelliVue Patient Monitors. The modification is the introduction of the models MP2 and X2 IntelliVue Patient Monitors and the introduction of software release F.00 for the entire IntelliVue Patient Monitors family, models MP2, X2, MP5, MP20, MP30, MP40, MP50, MP60, MP70, MP80, and MP90.
The Philips IntelliVue Patient Monitors (models MP2, X2, MP5, MP20, MP30, MP40, MP50, MP60, MP70, MP80, and MP90, with software release F.00) are intended for monitoring and recording multiple physiological parameters and generating alarms for adults, pediatrics, and neonates in hospital environments. Some models (MP2, X2, MP20, MP30, MP40, MP50) are also for hospital transport, and the MP5 is for transport outside the hospital. They are intended for use by healthcare professionals.
Acceptance Criteria and Device Performance:
The provided 510(k) summary states that "Pass/Fail criteria were based on the specifications cleared for the predicate devices." However, it does not provide specific quantitative acceptance criteria or detailed reported device performance metrics in a table. It generally states that "test results showed substantial equivalence" and that the "results demonstrate that the Philips IntelliVue Patient Monitors meet all reliability requirements and performance claims."
Acceptance Criteria (Generic as specific criteria are not provided) | Reported Device Performance (Generalized as specific metrics are not provided) |
---|---|
Device functions as intended without hazardous failures. | Testing established performance, functionality, and reliability. |
Meets safety and performance requirements. | Test results showed substantial equivalence to predicate devices. |
Conforms to EMC and environmental standards. | EMC and environmental test results were satisfactory. |
Maintains reliability. | Meets all reliability requirements. |
Study Details:
-
Sample size for the test set and data provenance:
The document does not specify the sample size for the test set or the data provenance (e.g., country of origin, retrospective/prospective). It only mentions "system level and regression tests, safety and performance tests, EMC and environmental tests, such as testing from the hazard analysis." -
Number of experts used to establish the ground truth for the test set and qualifications:
This information is not provided in the document. -
Adjudication method for the test set:
This information is not provided in the document. -
Multi-reader multi-case (MRMC) comparative effectiveness study:
No MRMC comparative effectiveness study is mentioned. The submission focuses on demonstrating substantial equivalence to predicate devices through technical verification and validation, not comparative effectiveness with human readers. -
Standalone (algorithm only without human-in-the-loop performance) study:
The submission describes testing activities for the device itself ("Verification, validation, and testing activities establish the performance, functionality, and reliability characteristics of the modified devices"). This implies standalone performance testing of the device's functions, but details on specific standalone performance metrics or a study explicitly labeled as such are not provided. The device is a patient monitor, implying continuous monitoring of physiological parameters by the device itself before human interpretation. -
Type of ground truth used:
The document does not explicitly state the type of ground truth used for performance evaluation, beyond stating that "Pass/Fail criteria were based on the specifications cleared for the predicate devices." For physiological monitoring, ground truth would typically come from calibrated reference measurements or expert clinical assessment for phenomena like arrhythmia detection. -
Sample size for the training set:
This information is not provided. The document describes verification and validation activities for the device, but does not mention "training sets," which implies that this device might not incorporate machine learning or AI that requires a distinct training phase in the way a diagnostic imaging AI would. -
How the ground truth for the training set was established:
As no training set is explicitly mentioned or implied to be relevant to the device's development as described, this information is not provided.
Ask a specific question about this device
Page 1 of 1